Cargando…
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475056/ https://www.ncbi.nlm.nih.gov/pubmed/32632826 http://dx.doi.org/10.1007/s40265-020-01357-1 |